Intranasal Administration
Intranasal Administration - Related Videos
07:15
Intranasal Administration of CNS Therapeutics to Awake Mice
0 Views •
Cited by 182 •
2013
A method to intranasally administer drugs to awake mice for the purpose of targeting the brain is described. This method allows for repeat dosing over long periods using intranasal administration of drug without anesthesia, and nose-to-brain delivery with minimal systemic exposure.
06:32
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
0 Views •
Cited by 14 •
2016
We herein detail the methodology followed to compare protective efficacy and lung immune response induced by intranasal and subcutaneous immunization with BCG in mouse model. Our results show the benefits of pulmonary vaccination and suggest a role for IL17-mediated response in vaccine-induced protection.
03:37
Intranasal Drug Administration in Mice via Pipette and Reverse-Cannulation for Nose-to-Brain Drug Delivery
0 Views •
2025
Source: Kanazawa, T., et al. Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery. J. Vis. Exp. (2018)This video demonstrates the intranasal administration of radiolabeled drugs in an anesthetized mouse to achieve nose-to-brain drug delivery. It explains how drugs cross the nasal epithelium and travel via neuronal pathways to reach the brain, as well as how ciliary motion influences drug retention and clearance. Additionally, the video...
04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
0 Views •
2024
The present protocol describes a method for intranasal administration of α-synuclein aggregates. This method provides insights into α-synuclein propagation from the olfactory mucosa to the olfactory bulb in Parkinson's disease.
02:16
Intranasal Immunization with BCG in a Mouse Model
0 Views •
2025
This video demonstrates intranasal BCG immunization in mice, activating both innate and adaptive immune responses, leading to the development of lung-resident memory T cells and effector B cells, thus enhancing protection against Mycobacterium infections.
FAQs
Formulation characteristics, mucus interactions, and mucociliary clearance strongly influence how long a drug remains available for uptake. The formulation must allow the dose to dissolve in nasal mucus, while clearance can remove material before it crosses the epithelial lining. Dose volume and membrane permeability further shape the fraction absorbed, so these variables are central when interpreting exposure or optimizing delivery.
Dose volume is an important determinant of uptake, alongside formulation and membrane permeability. In pharmacology studies, changing the administered volume can change how much drug remains available at the nasal mucosa and therefore alter measured exposure. Keeping volume controlled helps distinguish effects of the drug or formulation from effects caused by the delivery condition itself.
Compared with oral dosing, intranasal administration may provide faster systemic exposure and can reduce gastrointestinal degradation and hepatic first-pass metabolism. These differences can influence how quickly a drug appears in circulation and how much of the administered dose remains available. Pharmacologists therefore compare the two routes when evaluating exposure patterns and the consequences of route selection.
It is relevant because the nasal route provides a platform for investigating nose-to-brain transport, in addition to local nasal and systemic outcomes. Pharmacology studies can therefore examine whether a formulation or delivery condition supports distribution of interest beyond conventional systemic exposure. The source context identifies this as an area of investigation, not as a guaranteed outcome for every intranasal drug.
Evaluation focuses on depositing a defined formulation in the nasal cavity, allowing the drug to dissolve in mucus, and assessing uptake across the epithelial lining. Investigators then distinguish local effects from systemic exposure and relate findings to clearance, dose volume, formulation, and permeability. This workflow connects physical delivery conditions with pharmacological outcomes without assuming that every dose produces the same distribution.
Applications span both local therapy and broader drug delivery. Nasal decongestion and allergy relief use the route for effects in the nasal region, whereas vaccines and selected emergency medicines illustrate other therapeutic contexts. These examples show why pharmacologists evaluate intranasal products according to the intended outcome, whether that outcome is local action, systemic exposure, or rapid delivery.
Studies can measure local effects in nasal tissues, systemic exposure after absorption, or the feasibility of emergency delivery for selected medicines. They may also examine how formulation, clearance, dose volume, and permeability change uptake. Separating these outcomes helps researchers determine whether a preparation is acting primarily at the administration site or after entering circulation.